Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
Chronic enteropathy associated with SLCO2A1 gene (CEAS) is an autosomal recessive disorder caused by biallelic loss-of-function variants in SLCO2A1, encoding a prostaglandin E₂ transporter (PGT) ([PMID:26539716]). Patients develop persistent nonspecific small intestinal ulcers, chronic anemia, hypoalbuminemia, and protein-losing enteropathy, often misdiagnosed as Crohn’s disease.
Genetic studies have identified over 40 unrelated probands with CEAS in Japanese, Chinese, and other populations ([PMID:26539716]; [PMID:38755710]). A novel homozygous splice-altering variant, c.929A>G (p.Asp310Gly), was reported in a Chinese patient and confirmed by Sanger sequencing ([PMID:38862970]). Parental consanguinity in multiple families and recessive segregation support autosomal recessive inheritance.
The variant spectrum encompasses approximately 30–35 pathogenic alleles, including missense (e.g., c.547G>A (p.Gly183Arg)), splicing (c.940+1G>A), nonsense (p.Ser506Ter), and frameshift changes, with a Japanese founder splice-site mutation (c.940+1G>A) recurring in cohorts ([PMID:26539716]).
Functional assays in Xenopus laevis oocytes show that 10 of 11 CEAS-associated SLCO2A1 mutations markedly reduce PGE₂ transport capacity ([PMID:35877192]). In vitro minigene models and qPCR confirm that c.929A>G causes exon 7 skipping and abolishes normal transcript expression in patient tissues ([PMID:38862970]).
Clinically, CEAS patients present with chronic anemia, hypoalbuminemia, abdominal pain, diarrhea, and protein-losing enteropathy; >25% manifest primary hypertrophic osteoarthropathy features such as clubbing and periostosis ([PMID:29313109]).
Integration of genetic and functional data establishes loss-of-function of SLCO2A1 as the definitive cause of CEAS. Genetic testing for SLCO2A1 mutations is recommended in early-onset enteropathy with normal inflammatory markers unresponsive to conventional therapies. Key take-home: Biallelic SLCO2A1 mutations drive CEAS via defective prostaglandin transport, underpinning precision diagnosis and genetic counseling.
Gene–Disease AssociationDefinitiveOver 40 unrelated probands (PMID:26539716; PMID:38755710) with biallelic SLCO2A1 mutations and replicated functional deficits confirm the association Genetic EvidenceStrongBiallelic loss-of-function variants in >40 probands across multiple cohorts with autosomal recessive segregation Functional EvidenceStrongIn vitro assays demonstrate impaired PGE₂ transport for ≥10 patient-derived variants and splicing models confirm transcript loss |